Targeted cancer therapeutics: the heartbreak of success.
Mann
Douglas L
DL
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D016503:Drug Delivery Systems / Q000379:methods*; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006333:Heart Failure / Q000139:chemically induced / Q000503:physiopathology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*; D010879:Piperazines / Q000627:therapeutic use / Q000633:toxicity; D011743:Pyrimidines / Q000627:therapeutic use / Q000633:toxicity; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced / Q000503:physiopathology; D019061:src-Family Kinases / Q000009:adverse effects / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019061:src-Family Kinases